[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:17p":3},{"name":4,"total":5,"recruiting":5,"trials":6},"17p",6,[7,15,21,28,34,40],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT07053436","Horizon Two: HR NDMM (MMRC-100)",[11],"Phase 2","RECRUITING","2026-08-26T02:17:59.904383Z","2026-05-29T15:36:40.182475Z",{"nct_id":16,"title":17,"phases":18,"status":12,"updated_at":19,"content_modified":20},"NCT05469893","Immuno-PRISM (PRecision Intervention Smoldering Myeloma)",[11],"2026-08-26T02:18:55.570428Z","2026-05-05T02:43:27.482255Z",{"nct_id":22,"title":23,"phases":24,"status":12,"updated_at":26,"content_modified":27},"NCT03937635","Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma",[25],"Phase 3","2026-08-26T02:16:42.787115Z","2026-05-05T02:43:27.306737Z",{"nct_id":29,"title":30,"phases":31,"status":12,"updated_at":32,"content_modified":33},"NCT05254743","A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)\u002FSmall Lymphocytic Lymphoma (SLL)",[25],"2026-08-26T02:15:34.659160Z","2026-05-05T02:43:26.921381Z",{"nct_id":35,"title":36,"phases":37,"status":12,"updated_at":38,"content_modified":39},"NCT03128879","Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL",[11],"2026-08-03T03:15:35.967581Z","2026-04-29T02:57:57.177996Z",{"nct_id":41,"title":42,"phases":43,"status":12,"updated_at":45,"content_modified":46},"NCT04959175","Phase I\u002FII Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies",[44],"Phase 1\u002FPhase 2","2026-08-26T02:15:23.202838Z","2026-05-05T02:43:28.644953Z"]